FDA
-
-
-
-
-
-
-
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City
-
-
-
-
-
-
-
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS
-
-
-
-
-
-
-
Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
-
-
-
-
-
-
-
Eagle Pharmaceuticals (EGRX) Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02
-
-
-
-
-
-
-
Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride)
-
-
-
-
-
-
-
Eagle Pharmaceuticals (EGRX) Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA
-
-
-
-
-
-
-
Eagle Pharmaceuticals (EGRX) Submits IND for CAL02
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

